Senhwa Biosciences, Inc. announced the acceptance of early positive Phase 2 efficacy and safety data abstract for Silmitasertib in moderate COVID-19 patients at the ISIRV-WHO Virtual Conference-COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment being held on 19-21 October, 2021. The ongoing Phase 2 trial data will be presented at the conference. The conference will address the evolution, epidemiology and impact of SARS-CoV-2, influenza, RSV and other respiratory viruses, implications for surveillance strategies and progress on vaccines, antivirals, immunomodulators and other countermeasures. The efficacy and safety of Silmitasertib was evaluated in a randomized, open-label, 2 arm parallel-group controlled interventional prospective phase 2 study conducted in two sites in the US. Participants were randomized if they had signs or symptoms of moderate COVID-19 and a positive SARS-CoV-2 RT-PCR or equivalent testing. 20 participants were randomized in a 1:1 ratio to receive 1,000 mg BID oral dose Silmitasertib in addition to SOC/best supportive care or SOC/best supportive care alone for 14 days. During the study, no patients on the Silmitasertib arm received concomitant COVID-19 therapies. Senhwa Biosciences is the first and only Taiwan based company to demonstrate human efficacy against SARS-CoV-2 with its investigational anti-COVID19 therapy. Silmitasertib targets host cell protein, Casein Kinase 2, and this unique and strategic clinical approach is expected to be effective against the emerging SARS-CoV-2 variants.